+34 620 10 75 37info@nanbiosis.com

Singular

Singular

U23-S04. Sperm, Oocyte and embryo cryopreservation (On-site&Remote) OUTSTANDING

Read More

U22-S08. Dosing of test substances and non clinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING

Read More

U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING

Read More

U22-S06. In vivo safety and effcacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING

Read More

U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site)

Read More

U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site)

Read More

U22-S03. In vivo toxicology in rodent and non-rodent species (On-site)

Read More

U22-S02. In vivo experimental design/consultancy for preclinal studies (On-site&Remote)

Read More

U19-S03.

Clinical Analysis Laboratory

The clinical analysis laboratory that performs a wide variety of analysis: (biochemistry, hematology, coagulation, urine analysis, blood gas analysis, different biomarkers, hormones, allergens) in various animal species (rat, mouse, rabbit, pig, sheep, dog, and cat). Specific methodologies are used in each animal species, having all techniques validated according to their physiological and pathological identity. It also has a formulation laboratory equipped to formulate, reconstitute and guarantee the correct storage of the test products used in these studies.

Customer benefits

The laboratories are certified with ISO-9001 and Good Laboratory Practices (GLP), strict quality standards that allow the production of high-precision results.
Also, the studies can be performed under regulatory requirements too, since the performing institution is Certified for Good Laboratory Practices.
Therefore, studies can be carried out in compliance with the strict guidelines of regulatory agencies, ensuring the reliability and traceability of all results and tests carried out in their different services.

Target customer

The services offered in this unit may be of interest to different companies and laboratories that work within the pharmaceutical industry. Companies whose objective is to test possible candidates for molecules, drugs or medical devices.
With this service, companies and laboratories ensure that they report reliable and reproducible results in all their studies, guaranteeing the traceability and viability of analyzes obtained.

References

  1. J Bote, et al. Novel ex-vivo database of a murine model of colorectal cancer using optical coherence tomography. Surg Endosc (2022) 36:S325–S674
  2. V Lucas-Cava, et al. Prostatic artery occlusion: Initial findings on pathophysiological response in a canine prostate model. Translational Andrology and Urology. Transl Androl Urol 2022.
  3. Soria F, et al. Heparin coating in biodegradable ureteral stents does not decrease bacterial colonization-assessment in ureteral stricture endourological treatment in animal model. Transl Androl Urol. 2021 Apr;10(4):1700-1710.
  4. Baez-Díaz C, et al. Microencapsulated Insulin-Like Growth Factor-1 therapy improves cardiac function and reduces fibrosis in a porcine acute myocardial infarction model. Sci Rep. 2020 Apr 28;10(1):7166.
  5. Moreno-Lobato, B, et al. Use of nanomedicine in preclinical wound healing studies. FarmaJournal; Salamanca T 4, N.º 1, (Feb 2019): 178.
  6. Picado Román, N, et al. Drugs most used in experimental animals in a Research Center. FarmaJournal; Salamanca T 4, N.º 1, (Feb 2019): 236.
  7. Moreno-Lobato B, et al. Analytical Validation Study of Hematological Parameters under Good Laboratory Practice Regulations in Different Laboratory Animal Species. Thromb Haemost Res. 2019; 3(1): 1018.
  8. Ballestín A, et al. A Pre-clinical Rat Model for the Study of Ischemia reperfusion Injury in Reconstructive Microsurgery. J Vis Exp. 2019 Nov 8;(153).
  9. R Blázquez , et al. Altered hematological, biochemical and immunological parameters in a porcine myocardial infarction model: predictive biomarkers for the severity of myocardial infarction. Veterinary Immunology and Immunopathology 205 (2018) 49–57.
  10. Vela FJ, et al. Evaluation of antigen-induced synovitis in a porcine model: Immunological, arthroscopic and kinetic studies. BMC Vet Res. 2017. Apr 7;13(1):93.
Read More

U14-S06. Lymphocyte proliferation assay (On-site&Remote) OUTSTANDING

Lymphocyte proliferation assay

Read More